Study guide

16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

Board Certified Specialist in Renal Nutrition CSR

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Kidney Disease Foundations

1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk

2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment

2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry

3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools

3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss

4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History

4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment

5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality

5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment

6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning

6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances

7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients

7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy

8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy

8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)

9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients

9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD

10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support

10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support

11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities

11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure

12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends

12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories

13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics

13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence

14 Chapter 14: Domain 2 — Care Coordination, Communication & Education

14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support

15 Chapter 15: Domain 3 — Regulations & Quality Management

15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool

16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols

16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways

Key Takeaways Explain This Topic AI

Dietitian-managed protocols in dialysis units are physician-approved policies adopted under the medical director and state scope-of-practice rules; they do not create independent prescribing authority.

A sound protocol states the evidence base, inclusion and exclusion criteria, lab-based decision points, dose steps, monitoring intervals, escalation rules and documentation.

In a mineral-bone protocol, hypercalcemia calls for reducing calcium-based binders and active vitamin D before adding more calcium, and binder doses are tied to meals and snacks.

An iron protocol consistent with KDIGO 2026 starts IV iron in HD at ferritin 500 ng/mL or less and TSAT 30% or less, and holds routine iron above ferritin 700 ng/mL or TSAT 40%.

A nutrition-support pathway consistent with KDOQI 2020 moves from counseling to at least a 3-month oral supplement trial, then enteral feeding or a trial of IDPN if needs still are not met.

Last updated: September 2026

Why protocols are tested

Two CSR task statements apply: facilitate the use of protocols/algorithms used in medication management and utilize evidence-based protocols and guidelines (i.e., KDOQI) to deliver standardized care . In most U.S. dialysis units, much day-to-day adjustment of phosphate binders, active vitamin D, calcimimetics, iron and ESAs happens through approved protocols , and dietitians often run the mineral-bone and nutrition-support pathways. The exam expects you to apply a protocol correctly, spot a step that conflicts with current guidance, and know the limits of the dietitian's authority.

Authority and governance

Physician approval. Protocols are orders adopted by the facility, usually approved by the medical director and the patient's nephrologist, who remain responsible for medical care. The dietitian acts under the protocol, within state licensure and scope-of-practice law and facility policy .

No independent prescribing. Following a protocol is not independent prescribing. Changes outside the protocol, or any unclear case, go to the physician.

Plan-of-care link. Changes made under a protocol must appear in the plan of care, which must use "current evidence-based professionally-accepted clinical practice standards" (42 CFR 494.90).

Quality link. Protocol outcomes (for example, the share of patients with phosphorus in range) are QAPI indicators (§494.110). Protocols should be reviewed when guidelines change, for example after the KDIGO 2026 anemia update.

Anatomy of a well-built protocol

Purpose and evidence base. For example: "Phosphorus management per KDOQI 2020 statements 6.3.1–6.3.2 and KDIGO 2017 CKD-MBD."

Population: who is included (in-center HD adults) and excluded (pregnancy, hospitalized patients, transplant candidates within days of surgery).

Monitoring schedule: for example, calcium and phosphorus monthly and intact PTH every 3 months.

Decision points with explicit lab ranges and trends, not single values alone.

Stepwise actions with dose increments and maximums.

Hold and escalation rules: when to stop and call the physician (for example, calcium at or above 10.5 mg/dL, potassium at or above 6.0 mEq/L, or symptoms).

Education and adherence checks before any dose increase: binder timing, supply and cost.

Documentation and communication requirements.

Competency requirements for staff who use the protocol.

Example 1: Mineral-bone disorder pathway (illustrative)

Phosphorus above the target range:

Confirm the value and look for non-diet causes: missed treatments, inadequate Kt/V, very high PTH.

Review intake: phosphate additives, portion sizes, and binders with every meal and snack.

If adherence and diet are adequate, increase the binder by one step with meals, respecting limits on calcium-based binders.

Recheck the next month.

Calcium above the upper limit (for example, uncorrected above 10.2 mg/dL):

Reduce or stop calcium-based binders and switch to a non-calcium binder as the protocol allows.

Reduce active vitamin D ; notify the physician about calcimimetic options.

Never answer high phosphorus by adding more calcium when calcium is already high.

Intact PTH trends:

Rising toward or above about 9 times the upper limit of normal: consider active vitamin D or a calcimimetic per the physician's order, after correcting phosphorus and 25(OH)D.

Falling below about 2 times the upper limit of normal: reduce vitamin D and calcimimetics to avoid adynamic bone disease.

Hold calcimimetics if corrected calcium falls below the lower limit of normal.

Example 2: Iron and ESA pathway in hemodialysis (consistent with KDIGO 2026)

Finding Protocol action

Hb below target; ferritin 500 ng/mL or less and TSAT 30% or less; no active infection IV iron course per the facility regimen, then proactive maintenance

  • Ferritin above 700 ng/mL or TSAT 40% or higher Hold routine iron ; look for inflammation or infection
  • Active bacteremia or infection Hold IV iron; notify the physician
  • Hb at or below about 9–10 g/dL after correctable causes are fixed Start or increase the ESA per protocol

Hb nearing 11.5 g/dL Reduce the ESA dose; KDIGO recommends aiming below 11.5 g/dL, and FDA labeling advises reducing or interrupting near 11 g/dL

Dose adjustment timing Change the ESA dose no more often than every 4 weeks, unless Hb rises more than 1 g/dL in 2–4 weeks, in which case reduce it

Poor ESA response Work through iron, inflammation, blood loss, inadequate dialysis, hyperparathyroidism, B12 and folate

Iron indices are tested every 1–3 months in HD, and more often after dose changes, blood loss or hospitalization.

Example 3: Pre-dialysis hyperkalemia pathway

Potassium 5.6–5.9 mEq/L: review the diet (salt substitutes, juices, large portions, missed leaching), constipation, acidosis, drug causes, missed or shortened treatments and access recirculation. Counsel and recheck.

Persistent elevation: ask the physician to review the dialysate potassium bath and consider a potassium binder (patiromer or SZC, with correct spacing from other drugs).

Potassium at 6.0 mEq/L or higher, or symptoms or ECG changes: use the immediate physician notification and emergency pathway. Do not wait for the next monthly review.

Example 4: Nutrition-support pathway (consistent with KDOQI 2020)

Screen at least biannually. Do a comprehensive assessment when screening flags risk: 7-point SGA, intake, weight trend, nPCR and albumin in context.

Diagnose PEW or inadequate intake with a PES statement, and address causes: under-dialysis, depression, dentition, food access, acidosis.

Counsel and fortify (small frequent meals, protein-dense foods, eating during dialysis where the facility allows it).

Oral nutritional supplements: a trial of at least 3 months if counseling alone fails (2D).

Enteral feeding trial if oral intake remains inadequate (OPINION).

IDPN trial for maintenance HD patients whose needs cannot be met orally or enterally (2C). For PD, amino acid dialysate is not a general strategy but may be trialed when other routes fail.

Reassess monthly while unstable, with defined stop criteria and goals.

Implementing and auditing protocols

Gap analysis: compare current practice with guidelines, such as outdated iron ceilings or blanket 2 g potassium limits.

Engage stakeholders (medical director, nurses, pharmacists, dietitians), train staff and pilot the protocol with a PDSA cycle .

Audit and feedback: track the share of patients in range, protocol adherence and safety events (hypercalcemia, hypoglycemia, iron overload) through QAPI.

Update when evidence changes, and document the review date and approval.

Common exam traps

Increasing a calcium-based binder in a patient who is already hypercalcemic.

Continuing IV iron at ferritin 900 ng/mL "because TSAT is low."

A protocol step that tells the dietitian to diagnose or prescribe outside the approved order.

Jumping straight to IDPN without an adequate oral supplement trial.